
IndraLab
Statements
Hydroxychloroquine activates MTX1. 2 / 2
|
2
reach
"The multicenter clinical trial TOWARD (TCZ in combination with traditional DMARD therapy) [XREF_BIBR], together with a majority of patients treated with MTX, included 387 patients treated with chloroquine and hydroxychloroquine, sulfasalazine, LEF (N = 97), parenteral gold salts, or azathioprine."